Castle Biosciences(CSTL) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Castle Biosciences reported fourth quarter revenue of $87 million, leading to a total revenue of $344.2 million for the full year 2025, exceeding guidance [6][21] - Excluding DecisionDx-SCC and IDgenetix revenue, the revenue growth for 2025 would have been approximately 34% [7] - The adjusted gross margin for the fourth quarter was 76.3%, compared to 76.2% in the fourth quarter of 2024, while the full year gross margin was 69.2%, down from 78.5% in 2024 [22][24] - The net loss for the fourth quarter was $2.3 million, compared to net income of $9.6 million for the same period in 2024, and the full year net loss was $24.2 million, compared to net income of $18.2 million in 2024 [27] Business Line Data and Key Metrics Changes - Total test report volume for the year was 105,053, a 37% increase compared to 2024, with TissueCypher report volume growing by 86% [8][10] - DecisionDx-Melanoma delivered 39,083 test reports in 2025, representing 9% year-over-year growth, while TissueCypher delivered 39,014 test reports [10][11] - The number of new ordering clinicians for TissueCypher increased to 2,082 in 2025, up from 1,234 in 2024 [13] Market Data and Key Metrics Changes - The company noted a patient penetration of approximately 31% for DecisionDx-Melanoma and 11% for TissueCypher exiting 2025 [11][13] - The American Gastroenterological Association recognized TissueCypher as a significant prognostic test for Barrett's esophagus, which is crucial for identifying high-risk patients [12][13] Company Strategy and Development Direction - Castle Biosciences aims to drive growth through its core revenue drivers, DecisionDx-Melanoma and TissueCypher, while also expanding into dermatology with the AdvanceAD-Tx test [9][15] - The company plans to initiate a pipeline test for GI diseases and evaluate EIS technology in collaboration with SciBase [17][18] - M&A will continue to play a role in the company's growth strategy, focusing on tests that are near or at market and reimbursement [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth story, emphasizing disciplined execution and the strength of the balance sheet [9][20] - For 2026, the company anticipates total revenue of $340 million to $350 million, reflecting mid to high teens growth over 2025 [21] - Management highlighted the importance of FDA clearance for DecisionDx-Melanoma to enhance reimbursement discussions and adoption [43] Other Important Information - The company completed the acquisition of Previse and launched the AdvanceAD-Tx test, which is expected to contribute materially to revenue in 2027 or 2028 [8][15] - Total operating expenses for 2025 were $387 million, up from $323.4 million in 2024, driven by increased personnel costs and higher sales and marketing expenses [25][26] Q&A Session Summary Question: Update on NCCN guidelines for DecisionDx-Melanoma - Management noted that the current guidelines did not change the threshold for sentinel lymph node biopsy and highlighted the importance of their test in reducing unnecessary procedures [35][36] Question: Timeline for FDA approval of DecisionDx-Melanoma - The company is preparing a de novo 510(k) submission, with expectations for acceptance by the end of the year or early next year, which could impact clinician adoption [42][43] Question: Strategy for AdvanceAD-Tx test - The sales team is focusing on maintaining momentum for DecisionDx-Melanoma while gradually introducing AdvanceAD-Tx, with plans to shift sales focus as adoption increases [49][50] Question: Expectations for TissueCypher volume growth - Management expects continued volume growth for TissueCypher, driven by both existing ordering clinicians and new clinician adoption, although growth rates may moderate as penetration increases [75] Question: Impact of potential LCD for DecisionDx-SCC - Management indicated that if an LCD is published, they would fold DecisionDx-SCC back into the sales strategy, but timing and confidence in reimbursement will dictate the approach [81][82]